EUCTR2008-003230-22-IT进行中（未招募）不适用
Multicenter, open label, prospective study to evaluate the efficacy and safety of deferasirox 30 mg/kg/day for 52 weeks, in transfusion-dependent &#946;-thalassemic patients with cardiac MRI T2* <20 msec - ND
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Both sexes, aged ≥10 years β-thalassemic patients receiving regular transfusions with an history of at least 20 transfusional events Patients naive for deferasirox Serum ferritin levels ≥1000ng/mL (average of the last 6 months assays); Cardiac MRI T2* >5 and <20 msec. LVEF at MRI ≥56% Written Informed Consent obtained from the patient if adult or from the parents or the legal guardian for pediatric patients and consent of the pediatric patient themselves if capable of reading and understanding the meaning of the text Women of child bearing potential should use a valid contraceptive method.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients that have already started deferasirox therapy Existing contraindications to the performance of MRI procedure, including presence of metallic prostheses not compatible with the MRI procedure other than those approved as safe for use in MRI scanners (e.g., some types of aneurysm clips, shrapnel in proximity to vital organs such as the retina), pacemaker, intractable claustrophobia and incapability to follow the instruction for the correct performance of the MRI (e.g. to maintain a supine position, to hold breath, etc.) Clinical conditions requiring intensive chelating therapy on the basis of Investigator?s judgment Severe liver impairment of ALT (SGOT) and/or AST (SGOT) > 5 times upper limit of the normal range (ULN) Uncontrolled systemic hypertension Estimated creatinine clearance <60 mL/min History of nephrotic syndrome History of clinically significant ocular toxicity related to the chelating therapy Psychiatric disorders or drug dependence that might impair the capability of the patient to provide their Informed Consent or to be administered the study treatment Pregnancy or breastfeeding Any surgical or medical condition that might significantly alter the absorption, distribution, metabolism or elimination of the any drugs, particularly: 1) History of intestinal inflammatory disease, gastritis, ulceration, gastro-intestinal and/or rectal bleeding 2) History of major gastro-intestinal surgery, such as gastrectomy, gastro-enterostomy, intestinal resection 3) History of pancreatic damage or pancreatitis; signs of pancreatic failure, such as alteration of lipases or amylases serum levels 4) History or presence of renal insufficiency as indicated by alteration of serum creatinine or BUN levels 5) History of urinary obstruction or voiding difficulty Patient judged potentially non-compliant and/or non-cooperative with the study procedures Women of childbearing potential not using the contraception method(s) specified in this study (specify), as well as women who are breastfeeding Known sensitivity to study drug(s) or class of study drug(s) Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study (specify as required) Use of any other investigational agent in the last 30 days.
研究者
相似试验
已完成
4 期
A Post marketing study to assess the safety and efficacy of Capixyl Lotion (5%) in patients with Male Pattern Hair LossCTRI/2013/10/004104Glenmark Pharmaceuticals Ltd44
进行中（未招募）
1 期
Prospective, multicenter, open-label study to evaluate the efficacy of esmolol in the early identification of cardiovascular disorders induced by cirrhosis, diabetes mellitus, and cardiotoxic treatments (CIBER-bB-ECHO).Patients with cardiovascular alterations induced by cirrhosis, diabetes mellitus and cardiotoxic treatments.CTIS2024-514880-25-00Consorcio Centro De Investigacion Biomedica En Red1,000
进行中（未招募）
1 期
Clinical trial to evaluate the safety and efficacy of intravitreal ranibizumab in patients with choroidal neovascularization secondary to other causes than Age-related Macular Degeneration and Pathological Myopia.Patients with subfoveal or juxtafoveal choroidal neovascularization secondary to other causes than Age-related Macular Degeneration and Pathological Myopia (angioid streaks, pseudohistoplasmosis, inflammatory chorioretinal diseases and idiopathic lesions).MedDRA version: 13.1Level: LLTClassification code 10060837Term: Choroidal neovascularizationSystem Organ Class: 10015919 - Eye disordersEUCTR2009-014612-34-PTAIBILI - Association for Innovation and Biomedical Research on Light and Image20
进行中（未招募）
1 期
Multicenter, randomized, open-label study to evaluate the efficacy and safety of SOC + Sarilumab versus Standard of Care for the Early Treatment of COVID-19-pneumonia in Hospitalized PatientsEUCTR2020-002037-15-ESCristina Avendaño Sola200
已完成
4 期
A clinical trial to study the safety and efficacy of once daily Advagraf in patients who are undergoing kidney or liver transplantation.CTRI/2012/01/002361Astellas India Pvt Ltd200